StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Looks like best-case predictions are coming true

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Dec 29, 2021 11:28am

163 Views

Post# 34267691

RE:RE:RE:RE:Looks like best-case predictions are coming true

And to claim a loss you can't buy the same stock back for 30 days.

Nailbiter1 wrote:

For Canada, the last day for tax-loss selling in 2021 is
December 29.
Stocks purchased or sold after this date will be settled in 2022, so any capital gains or losses will apply to the 2022 tax year.

The system differs in the US, and based on information from the IRS, the last day for tax-loss selling this year is December 31.

jopatclo wrote:
Last Day for Tax loss selling is today Dec29th !!

NewToInvesting7 wrote: Was it confirmed that StageZero is one of the PCR testing companies that are suffering backlog, ad/or unprecedented demand for its PCR tests? Would be nice if it is one of those companies, since we were told that they have a daily capacity of 3,000 tests (if I recall correctly). Otherwise we are all just guessing at the revenues.

Significant Covid testing revenues in Q4 would be great to help with operating expenses, but it’s the cancer testing that I most look forward to. Hoping it would at least be between $650k-$1m in Q4.

Regardless, for me personally, I've connected with Matt (COO), and am comfortable that this company will do well in the years ahead. Matt appears to have a level head, and can execute on James' vision, something that James struggled with (at least from my limited POV). Hope to see this on a nice steep upwards movement mid-late 2022.

Cheers!

gojotv! wrote:
The unprecedented demand for Covid tests (backlogs reported) will provide that nice, thick, revenue runway for the growth of Aristotle testing and the international deployment of Care Oncology's treatment protocol.

The fact that the "targets" have been reached (or will soon) bodes well for the next financials.

Expect a great New Year's surprise!

Cheers, and Happy Holidays!